Dimensional Fund Advisors LP Has $268.88 Million Stock Position in Humana Inc. (NYSE:HUM)

Dimensional Fund Advisors LP boosted its holdings in shares of Humana Inc. (NYSE:HUM - Free Report) by 1.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,059,737 shares of the insurance provider's stock after buying an additional 19,091 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.88% of Humana worth $268,877,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. FPC Investment Advisory Inc. acquired a new stake in Humana during the 4th quarter valued at $27,000. Centricity Wealth Management LLC bought a new stake in shares of Humana during the 4th quarter worth about $30,000. LFA Lugano Financial Advisors SA grew its stake in Humana by 56.3% in the 4th quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider's stock valued at $32,000 after buying an additional 45 shares during the last quarter. OFI Invest Asset Management acquired a new stake in Humana during the fourth quarter worth approximately $33,000. Finally, Atwood & Palmer Inc. boosted its holdings in shares of Humana by 64.5% during the fourth quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider's stock worth $39,000 after acquiring an additional 60 shares during the period. Institutional investors own 92.38% of the company's stock.

Humana Price Performance

Humana stock opened at $246.07 on Tuesday. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76. Humana Inc. has a one year low of $213.31 and a one year high of $406.46. The stock's 50 day moving average is $265.62 and its 200 day moving average is $270.27. The firm has a market cap of $29.70 billion, a P/E ratio of 24.73, a P/E/G ratio of 2.05 and a beta of 0.62.

Humana (NYSE:HUM - Get Free Report) last released its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. As a group, research analysts expect that Humana Inc. will post 16.47 EPS for the current year.

Humana Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be given a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a dividend yield of 1.44%. The ex-dividend date of this dividend is Friday, June 27th. Humana's dividend payout ratio (DPR) is 35.58%.

Wall Street Analyst Weigh In

Several analysts recently issued reports on HUM shares. Royal Bank of Canada restated an "outperform" rating and issued a $283.00 price target on shares of Humana in a research note on Wednesday, February 12th. Guggenheim assumed coverage on shares of Humana in a report on Wednesday, April 9th. They issued a "buy" rating and a $326.00 price objective for the company. Mizuho lifted their price target on shares of Humana from $305.00 to $316.00 and gave the company an "outperform" rating in a research report on Wednesday, April 9th. JPMorgan Chase & Co. lowered their price objective on Humana from $257.00 to $256.00 and set a "neutral" rating on the stock in a research note on Tuesday, February 18th. Finally, Morgan Stanley reduced their target price on Humana from $301.00 to $285.00 and set an "equal weight" rating on the stock in a report on Wednesday, February 12th. Seventeen investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat.com, Humana presently has an average rating of "Hold" and an average target price of $284.90.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.